Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting Usha Sharma Jun 6, 2016 HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast…
